Article information
Resumen
Describimos el caso de un paciente de 36 años con artritis reumatoide y miastenia gravis sin respuesta al tratamiento inmunosupresor convencional, quien recibió tratamiento con terapia anti CD-20 (rituximab), con adecuada respuesta clínica de sus dos patologías autoinmunes de base.
Palabras clave:
artritis reumatoide
miastenia gravis
rituximab
Summary
The following case presents a 36 year-old patient with rheumatoid arthritis and myasthenia gravis without response with the conventional immunosuppressive treatment, who was managed with anti CD-20 therapy (rituximab), with good clinical evolution of both autoinmune diseases.
Key words:
rheumatoid arthritis
myasthenia gravis
rituximab
Full text is only aviable in PDF
Referencias
[1.]
D. Grob, N. Brunner, T. Namba, M. Pagala.
Lifetime course of myasthenia gravis.
Muscle Nerve, 37 (2008), pp. 141-149
[2.]
B.M. Conti-Fine, M. Milani, H.J. Kaminski.
Myasthenia gravis: past, present and future.
J Clin Invest, 116 (2006), pp. 2843-2854
[3.]
J.C. Keesey.
Clinical evaluation and management of myasthenia gravis.
Muscle Nerve, 29 (2004), pp. 484-505
[4.]
A. Jani-Ascadi, R. Lisak.
Myasthenic crisis: guidelines for prevention and treatment.
J Neurol Sci, 261 (2007), pp. 127-133
[5.]
S. Sathasivam.
Steroids and immunosuppresant drugs in myasthenia gravis.
Nature Clin Pract Neurol, 4 (2008), pp. 317-327
[6.]
D.P. Richmann, M.A. Agius.
Treatment of autoinmune myasthenia gravis.
Neurology, 61 (2003), pp. 1652-1661
[7.]
Y. Renaudineau, V. Devauchelle-Pensec, C. Hanrotel, J.O. Pers, A. Saraux, P. Youinou.
Monoclonal anti CD 20 antibodies: mechanism of action and monitoring of biological effects.
Joint Bone Spine, 76 (2009), pp. 458-463
[8.]
R.J. Looney, R. Srinivasan, L.H. Calabrese.
The effects of rituximab on immunocopetency in patients with autoinmune disease.
Arthritis Rheum, 58 (2008), pp. 5-14
[9.]
F. Zaja, D. Russo, G. Fuga, G. Perella, M. Baccarani.
Rituximab for myasthenia gravis developing after bone marrow transplant.
Neurology, 55 (2000), pp. 1062-1063
[10.]
M.E. Wylam, P.M. Anderson, N.L. Kuntz, V. Rodríguez.
Succesfull treatment of refractary myasthenia gravis using rituximab: a pediatric case report.
J Pediatr, 143 (2003), pp. 674-677
[11.]
A. Gajra, N. Vajpayee, S.J. Grethlein.
Response of myasthenia gravis to rituximab in a patient with non Hodgkin lymphoma.
Am J Hematol, 77 (2004), pp. 196-197
[12.]
B. Hain, K. Jordan, M. Deschauer, S. Zierz.
Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
Muscle Nerve, 33 (2006), pp. 575-580
[13.]
M.N. Meriggioli.
Myasthenia gravis: immunopathogenesis, diagnosis, and management.
Continuum Lifelong Learning Neurol, 15 (2009), pp. 35-62
[14.]
N. Wakata, A. Nakazato, H. Sugimoto, H. Iguchi, R. Saito.
A case of myasthenia gravis accompanied by erythema elevatum diutinum and rheumatoid arthritis.
J Neurol, (2001), pp. 435-436
[15.]
E.C. Gowing, K.M. McKown.
Myasthenia gravis in a patient with pauciarticular juvenile chronic arthritis.
J Clin Rheumatol, 8 (2002), pp. 269-272
[16.]
C.L. Maters, R.L. Dawkins, P.J. Zilko.
Penicillamineassociated myasthenia gravis, anti acetylcholine receptor and antistriational antibodies.
Am J Med, 63 (1977), pp. 689-694
[17.]
R.L. Dawkins, M.J. Garlepp, B.L. McDonald, J. Williamsom, P.J. Zilko, J. Carrano.
J Rheumatol Suppl, (1981), pp. 169-172
[18.]
V. Jan, A. Callens, L. Machet, M.C. Machet, G. Lorette, L. Vaillant.
D-penicillamine-induced pemphigus, polumiositis, and myasthenia.
Ann Dermatol Venereol, 126 (1999), pp. 153-156
[19.]
Y. Kato, Y. Naito, Y. Narita, S. Kuzuhara.
D-penicillamineinduced myasthenia gravis in a case of eosinophilic fascitis.
J Neurol Sci, 146 (1997), pp. 85-86
[20.]
S. Kerkeni, H. Marotte, P. Miossec.
Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
Muscle Nerve, 38 (2008), pp. 1343-1345
Copyright © 2010. Asociación Colombiana de Reumatología
